Nemes Rush Group LLC Trims Stock Holdings in MiMedx Group, Inc. (NASDAQ:MDXG)

Nemes Rush Group LLC cut its holdings in shares of MiMedx Group, Inc. (NASDAQ:MDXG) by 45.2% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,380 shares of the company’s stock after selling 6,921 shares during the quarter. Nemes Rush Group LLC’s holdings in MiMedx Group were worth $73,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in MDXG. Vanguard Group Inc. raised its holdings in MiMedx Group by 4.1% in the third quarter. Vanguard Group Inc. now owns 6,437,155 shares of the company’s stock valued at $46,927,000 after acquiring an additional 250,812 shares in the last quarter. Cannell Capital LLC increased its position in shares of MiMedx Group by 106.7% in the 3rd quarter. Cannell Capital LLC now owns 2,273,762 shares of the company’s stock worth $16,576,000 after purchasing an additional 1,173,506 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of MiMedx Group by 5.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,134,213 shares of the company’s stock valued at $9,947,000 after purchasing an additional 57,704 shares in the last quarter. EAM Investors LLC lifted its position in shares of MiMedx Group by 20.9% during the third quarter. EAM Investors LLC now owns 664,213 shares of the company’s stock worth $4,842,000 after purchasing an additional 114,880 shares during the last quarter. Finally, Russell Investments Group Ltd. grew its stake in MiMedx Group by 1,577.5% in the fourth quarter. Russell Investments Group Ltd. now owns 525,059 shares of the company’s stock worth $4,605,000 after purchasing an additional 493,759 shares in the last quarter. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on MDXG. Lake Street Capital initiated coverage on MiMedx Group in a research note on Thursday, March 7th. They set a “buy” rating and a $12.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $11.00 price target on shares of MiMedx Group in a research report on Wednesday, May 1st. Mizuho lifted their price objective on shares of MiMedx Group from $13.00 to $14.00 and gave the stock a “buy” rating in a report on Friday, March 1st. Finally, StockNews.com cut shares of MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, May 3rd. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $12.25.

MiMedx Group Stock Performance

Shares of NASDAQ MDXG traded down $0.05 during mid-day trading on Wednesday, hitting $7.90. The company had a trading volume of 82,327 shares, compared to its average volume of 775,487. MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $9.27. The stock has a market cap of $1.17 billion, a price-to-earnings ratio of 18.07 and a beta of 1.44. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.29 and a quick ratio of 2.71. The firm’s 50 day simple moving average is $7.22 and its two-hundred day simple moving average is $7.70.

MiMedx Group (NASDAQ:MDXG) last posted its earnings results on Tuesday, April 30th. The company reported $0.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.04 by $0.03. MiMedx Group had a return on equity of 39.42% and a net margin of 18.63%. The company had revenue of $84.71 million for the quarter, compared to analysts’ expectations of $79.36 million. As a group, equities research analysts forecast that MiMedx Group, Inc. will post 0.34 earnings per share for the current year.

Insider Activity at MiMedx Group

In other MiMedx Group news, CAO William Frank Iv Hulse sold 20,381 shares of the firm’s stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $7.95, for a total value of $162,028.95. Following the sale, the chief accounting officer now owns 479,959 shares in the company, valued at $3,815,674.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is currently owned by insiders.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.